An investigational anticoagulant that targets factor XI failed to prevent arteriovenous graft (AVG) thrombosis in chronic hemodialysis patients, according to a placebo-controlled phase IIb trial.

In 502 patients with end-stage kidney disease (ESKD) receiving hemodialysis via AVG, time to a graft thrombosis event was not significantly different for those on 6 mg of MK-2060 (HR 0.83, 95% CI 0.58-1.19) or 20 mg of MK-2060 (HR 0.87, 95% CI 0.60-1.26) compared with placebo in an intention-to-treat population, said Wolfgang Winkelmayer, MD, ScD, of Baylor College of Medicine in Houston.

Median time to first AVG thrombosis event in the overall study population -- defined as the sudden occlusion of the AVG requiring thrombectomy or thrombolysis or other clinical evidence of AVG thrombosis confir

See Full Page